Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Net Income towards Common Stockholders (2021 - 2023)

Historic Net Income towards Common Stockholders for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$25.6 million.

  • Cullinan Therapeutics' Net Income towards Common Stockholders rose 555.66% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 24197.15%. This contributed to the annual value of -$167.6 million for FY2024, which is 804.25% down from last year.
  • Cullinan Therapeutics' Net Income towards Common Stockholders amounted to -$25.6 million in Q4 2023, which was up 555.66% from -$39.2 million recorded in Q3 2023.
  • In the past 5 years, Cullinan Therapeutics' Net Income towards Common Stockholders registered a high of $174.1 million during Q2 2022, and its lowest value of -$58.1 million during Q1 2023.
  • In the last 3 years, Cullinan Therapeutics' Net Income towards Common Stockholders had a median value of -$25.2 million in 2022 and averaged -$9.4 million.
  • Over the last 5 years, Cullinan Therapeutics' Net Income towards Common Stockholders had its largest YoY gain of 115885.39% in 2022, and its largest YoY loss of 100627.2% in 2022.
  • Quarter analysis of 3 years shows Cullinan Therapeutics' Net Income towards Common Stockholders stood at -$34.2 million in 2021, then increased by 20.87% to -$27.1 million in 2022, then grew by 5.56% to -$25.6 million in 2023.
  • Its Net Income towards Common Stockholders stands at -$25.6 million for Q4 2023, versus -$39.2 million for Q3 2023 and -$32.2 million for Q2 2023.